Rheuma steroidale antirheumatika

nr-axSpA pts were more often female than AS pts (52% vs. 70%), were younger (mean age ±11 vs. ± years), and had a shorter symptom duration (± vs. ±±11 years) but were similarly often HLA-B27+ (74% vs. 80%), all p=.. Significant differences between the groups were found in mean CRP levels (± vs. ±) and mean MRI scores (± vs. ±) in nr-axSpA vs. AS pts, respectively, both p in 76% and 74% and a positive MRI occurred in 70% and 78% of pts with nr-axSpA and AS, respectively. After wk1 and wk4, both groups showed similarly increased rates in the NSAID-index and also similar responses to NSAIDs, with significant improvement from BL in all assessments with the exception of CRP levels and MRI-a scores, where almost no changes were observed. At wks 1 and 4, an ASAS20% response was found in 40% (21% with nr-axSpA and 19% with AS) and in 52% of pts (23% nr-axSpA and 29% AS), while ASAS partial remission was found in 10% (4% nr-axSpA and 6% AS) and in 16% of pts (7% nr-axSpA and 9% AS), respectively. However, 49% and 44% of all pts still had a BASDAI ?4 at wks 1 and 4, and similar results were found for an ASDAS-CRP cut-off of ?, with 37% and 33% achieving this at wks 1 and 4 (no differences between nr-axSpA and AS).

Rheuma steroidale antirheumatika

rheuma steroidale antirheumatika


rheuma steroidale antirheumatikarheuma steroidale antirheumatikarheuma steroidale antirheumatikarheuma steroidale antirheumatikarheuma steroidale antirheumatika